The limited access to high-quality biologicals due to the cost of treatment constitutes an unmet medical need in the US and other regions of the world [1].
Worldwide biosimilar development
Biosimilars/Research | Posted 29/04/2011 0 Post your comment
Use of biosimilar products has already decreased the cost of treatment in many regions of the world. With the approval of the Biologics Price Competition and Innovation Act, which was signed into law on 23 March 2010 by President Barack Obama, a regulatory pathway for approval of these products has been established in the US.
The FDA is however somewhat behind, with the EMA being the first to apply the concept of ‘comparability’ to biosimilars and having already approved its first biosimilars back in 2006.
Between 2011 and 2015 patents on more than 30 branded biologicals with sales of US$51 billion will lose their patent exclusivity and biosimilar versions of these important medicines are already in development.
The Biologics Price Competition and Innovation Act, once guidance has been put in place, will allow the FDA to approve biosimilars, and will also allow the FDA to make decisions on the interchangeability of biosimilars with their reference products.
The authors conclude that the approval of biosimilars will facilitate patient access and lower costs, thus making healthcare dollars available for the next generations of originator medicines.
The series of five articles that follow discuss the issues surrounding biosimilars covering topics from opportunities to regulatory requirements and the possibilities of substitution.
Related articles
Need for a global pathway for biosimilars
Interchangeability or substitution of biosimilars
Opportunities for biosimilar development
Regulatory approach to biosimilar development
Comparability for biosimilar development
Acceptable changes in quality for glycosylated biologicals
Global biosimilar market to grow to US$3.7 billion in 2015
Reference
1. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209-17. doi:10.4161/mabs.3.2.15005
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment